Here’s how BioPhorum’s ‘one voice’ is helping industry save $millions in Colombia

31 May 2022
Drug Substance

Imagine a situation where post-approval changes took 18–24 months to be reviewed. Think about the impact on biomanufacturers who would need staggered timelines for implementing changes across different markets and different products. And their need for complex processes that affect inventories, time, money, resources, security, compliance, etc.

This was the picture facing biotherapeutic importers into Colombia because its health agency, INVIMA, took a long time to review post-approval changes that might only take six months elsewhere (or do not require any review). This is because INVIMA has limited resources for post-approval changes and has some extra requirements that are different from other agencies and so it reviewed any change (even with no impact on product quality).

This is why BioPhorum was asked to step in to bring its global harmonization experience to the table and apply its broad industry knowledge and its ability to work directly with regulatory agencies. In Colombia, the situation was even more complex than in other countries, as INVIMA’s ways of working were a direct consequence of a governmental decree. Direct interaction with the Colombian Ministry of Health was therefore also required to get the decree modified.

Significant impact

Why is this a big deal? Well, Colombia is third in LATAM countries in terms of spending on pharmaceuticals and biologics.

This situation is having a significant impact on manufacturers. Until a change is approved, they cannot distribute an amended product in that market and must distribute the old one. As well as holding expensive inventories, there is a compliance risk because manufacturers must be 100% sure they send the right product to the right market.

It also means manufacturers cannot react quickly enough if there is an urgent need for an older product, which might need to be manufactured. This would need more testing and submission work, cause increased costs and supply delays, and increase the risk of mistakes and products being rejected by the regulator.

Industry group collaboration

The AFIDRO and ANDI industry groups had been pushing for a change by demonstrating to INVIMA and the Ministry of Health that harmonization on post-approval submissions would help prevent stock-outs and ensure patient access to drugs. At the end of 2019, the groups asked BioPhorum for help as they hoped a global perspective would add value to the case for change.

Using BioPhorum’s post-approval strategy expertise, we created a team to examine Colombia’s regulatory environment around post-approval changes. We secured a meeting with INVIMA in April 2020, but this was postponed when Covid struck.

However, we used this pause to develop and align our position with AFIDRO and ANDI so that when we eventually spoke to INVIMA, we had one voice representing the global and local industries.

BioPhorum actions

At the end of 2021, AFIDRO arranged another meeting for us with INVIMA. We explained the benefits of harmonizing the requirements for post-approval changes with the WHO guidelines adopted by many other agencies, such as simplifying INVIMA’s review of documents.

We also discussed how using files from other agencies that have approved a change could save INVIMA’s resources and contribute to manufacturing efficiencies. Our successful work with the Brazilian regulator was a significant factor in the Colombian agency listening to us.

The agency agreed with our proposals but, unfortunately, a barrier to progress was that Colombian post-approval changes are governed by a government decree, not just a guideline, which was more difficult to amend.

To overcome this, we needed to talk to the Colombian Ministry of Health, which is responsible for new regulations and amendment issuance in Colombia. AFIDRO arranged this meeting for December 2021, where we explained the differences in the WHO guidelines and why Colombia should have a harmonized regulation for post-approval changes.

Presidential sign-off

The result is that the amended decree was signed off in March 2022. As a result, post-approval changes will now be reviewed by INVIMA according to WHO guidelines and in much shorter timescales than currently.

“There is no doubt that BioPhorum’s expertise has helped us on the path towards regulatory harmonization,” said Diana Chavarro, Regulatory Policy and Intelligence PACA Partner at Bayer. “As one of our industry priorities in Colombia, we will hopefully soon see an improvement in the efficiency in our post-approval change timelines.”

Planning for success, INVIMA is preparing its new post-approval change guideline, which is intended to go live by August 2022. BioPhorum will be supporting this public consultation before the final issuance.

This is a superb example of BioPhorum’s collaborative approach and how its ‘one voice’ strategy is improving harmonization across the global biopharmaceutical industry. Building on its success in Brazil and Colombia, the regulatory team plans to address similar issues in other countries – such as South Korea – to improve the review of post-approval changes.

Chinese Flag Fluttering In The Wind
What’s changing in the Chinese CMC regulatory environment?
Four Circles Depicting A Lifecycle Process
Optimizing your post-approval changes to save time, resources and money

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.


BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.


Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Partner

Supply Partner is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.


Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Inaugural BioPhorum Quality face to face – get involved
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
Delivering a Cell and Gene Therapy Outbound Supply Chain Pathway for the Industry
DNA and Earth on blue background
A vision for the biopharmaceutical industry’s inbound supply chain
A major milestone – a harmonized approach to product carbon footprint data
Technology Roadmap V 2.0
BioPhorum Technology Roadmapping roadmap vision 2.0


Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.


Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.


BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.


A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Bioreactivity testing in single-use system biomanufacturing